PAI-1 and TAFI in inflammatory bowel disease: the yin and yang of the fibrinolytic system : European Journal of Gastroenterology & Hepatology

Secondary Logo

Journal Logo

Leading Articles

PAI-1 and TAFI in inflammatory bowel disease: the yin and yang of the fibrinolytic system

Danese, Silvioa; Papa, Alfredob

Author Information
European Journal of Gastroenterology & Hepatology 20(9):p 826-828, September 2008. | DOI: 10.1097/MEG.0b013e3282faa769
  • Free



In both Crohn's disease and ulcerative colitis, the two major forms of inflammatory bowel disease (IBD), an increased risk of thrombotic events has been demonstrated. Pathogenesis of thrombosis is multifactorial as various primary coagulation system abnormalities other than acquired factors have been reported.

The fibrinolytic system has been widely investigated in IBD. Most of the available data report an imbalance in fibrinolytic capacity with a tendency toward a hypofibrinolytic state.

Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 are fundamental inhibitors of the fibrinolytic process and are also considered to be acute-phase reactants. Recent studies have shown an imbalance of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor, suggesting that these molecules might contribute to thromboembolic events in both forms of IBD.

Inflammatory bowel disease and alterations of fibrinolysis

Inflammation and coagulation play crucial roles in the pathogenesis of multiple chronic inflammatory disorders including Crohn's disease and ulcerative colitis, the two major forms of inflammatory bowel disease (IBD). A growing amount of data highlights a tight mutual network in which inflammation, coagulation, and fibrinolysis play closely related roles. In both forms of IBD, a hypercoagulable state and a prothrombotic condition exist, whereas coagulation abnormalities are an intimate part of the IBD clinical picture [1]. Indeed, IBD patients frequently suffer from thromboembolic events (TEs), which represent an important cause of morbidity and mortality [2,3]. Recently, a population-based study has found that IBD patients have a three-fold increased risk of developing deep venous thrombosis and pulmonary embolism than the general population [4]. This finding has been reinforced by another study, which demonstrated that TEs are a specific feature of IBD, as neither rheumatoid arthritis (another chronic inflammatory disease) nor celiac disease (another chronic bowel disease) displays an increased risk of TEs compared with controls [5].

It appears that both the arterial and venous systems may be involved. TEs occur more often in the deep vein of the leg and in pulmonary circulation, but they have been described to occur less frequently in other sites, such as the cerebrovascular system, portal vein, mesenteric veins, and retinal vein [6–11]. Arterial TEs occur less frequently in patients with IBD than venous TEs, and the majority occur after surgery. Arterial TEs may also affect several vascular districts [12–15].

The reasons for the increased occurrence of TEs in IBD are not completely understood. Several qualitative and quantitative abnormalities in hemostatic parameters in IBD patients have been reported [16–20] (Table 1), but no consistent unifying etiology has been identified to explain TEs in IBD patients. It has been suggested that in the majority of thrombotic IBD patients, at least one prothrombotic risk factor can be detected [21,22], but other authors [3] have indicated that approximately half of IBD patients develop TEs without any identifiable reason, reinforcing the hypothesis that IBD represents a risk factor per se for thrombosis.

Table 1:
Abnormalities of hemostatic parameters observed in inflammatory bowel disease patients

Also, the fibrinolytic system has been widely investigated in IBD as a prothrombotic condition may also result from reduced fibrinolytic activity (Fig. 1). Under physiological conditions, both coagulation and fibrinolysis are precisely regulated by multiple factors that, acting in a coordinated way, ensure blood fluidity while preventing blood loss, in particular in response to vascular injury. Briefly, adhesion, activation, and aggregation of platelets are the first steps of hemostasis, which are followed by activation of coagulation (clot formation) and finally by the fibrinolytic process (clot dissolution). An essential component of the fibrinolytic system is the zymogen plasminogen, which is converted to plasmin by tissue plasminogen activator (tPA) as well as by urokinase plasminogen activator (uPA); it is inhibited by plasminogen activator inhibitor-1 and plasminogen activator inhibitor-2 (PAI-1, PAI-2) and α2-antiplasmin (Fig. 1). Once formed, plasmin cleaves fibrin, generating soluble degradation products. Recently, thrombin-activatable fibrinolysis inhibitor (TAFI) has been characterized and its active form (TAFIa) is a potent attenuator of fibrinolysis, working by inhibiting plasmin generation, stabilizing fibrin thrombi, and establishing a regulatory connection between coagulation and fibrinolysis [23].

Fig. 1:
The fibrinolytic process (boxed molecules are inhibitors). FDP, fibrin degradation products; FgDP, fibrinogen degradation products: PAI, plasminogen activator inhibitor; TAFI, thrombin activatable fibrinolysis inhibitor; tPA, tissue-type plasminogen activator; uPA, urokinase plasminogen activator.

In this issue of the European Journal of Gastroenterology & Hepatology, Koutroubakis et al. [24] found, in a Greek population of IBD patients, increased PAI-1 plasma levels, but decreased TAFI plasma levels, compared with healthy controls. They concluded that an imbalance of fibrinolysis occurs in IBD. The literature data are in agreement with the findings of Koutroubakis et al. regarding the increased PAI-1 levels, whereas the only other study that has evaluated the levels of TAFI in IBD reports opposite conclusions, showing increased levels of TAFI [25]. Moreover, a fair amount of evidence demonstrates that PAI-1 and TAFI are acute-phase reactants with a linear correlation with other markers of inflammation. However, data obtained in IBD patients and in other chronic inflammatory disorders, such as Behçet's disease, are not conclusive [24–26]. It is important to keep in mind that the interpretation of the studies regarding hemostatic variables, such as PAI-1 or TAFI, are problematic because of the intra-assay and inter-assay variability of the different tests, pretest circumstances (i.e. modalities of sampling), and laboratory handling that may influence the results. In IBD, the comparisons of the different studies are further complicated by additional factors, such as differences in the clinical and demographic features of the patients studied and the disease activity evaluation. Moreover, some polymorphisms throughout the TAFI gene were recently identified and some of them may predispose some more than others to thrombosis development, although this point is still controversial [27]. In conclusion, data obtained by Koutroubakis et al. reinforce the notion that IBD is a prothrombotic disease, and the intricate relationship among coagulation, fibrinolysis, and inflammation. Future studies are needed to better elucidate the role of fibrinolysis abnormalities in the pathogenesis of thrombotic events in IBD patients.


Conflict of interest: none declared.


1. Danese S, Papa A, Saibeni S, Repici A, Malesci A, Vecchi M. Inflammation and coagulation in inflammatory bowel disease: the clot thickens. Am J Gastroenterol 2006; 101:1–13.
2. Talbot RW, Heppell J, Dozois RR, Beart RW Jr. Vascular complications of inflammatory bowel disease. Mayo Clin Proc 1986; 61:140–145.
3. Jackson LM, O'Gorman PJ, O'Connell J, Cronin CC, Cotter KP, Shanahan F, et al. Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and Factor V Leiden. QJM 1997; 90:183–188.
4. Bernstein CN, Blanchard JF, Houston DS, Wajda S. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost 2001; 85:430–434.
5. Miehsler W, Reinish W, Valic E, Osterode W, Tillinger W, Feichtenschlager T, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut 2004; 53:542–548.
6. Johns DR. Cerebrovascular complications of inflammatory bowel disease. Am J Gastroenterol 1991; 86:367–370.
7. Maccini DM, Berg JC, Bell GA. Budd–Chiari syndrome and Crohn's disease. An unreported association. Dig Dis Sci 1989; 34:1933–1936.
8. Schneiderman JH, Sharpe JA, Sutton DM. Cerebral and retinal vascular complications of inflammatory bowel disease. Ann Neurol 1979; 5:331–337.
9. Keyser BJ, Hass AN. Retinal vascular disease in ulcerative colitis. Am J Ophthalmol 1994; 118:395–396.
10. Hatoum OA, Spinelli KS, Abu-Hajir M, Attila T, Franco J, Otterson MF, et al. Mesenteric venous thrombosis in inflammatory bowel disease. J Clin Gastroenterol 2005; 39:27–31.
11. Umit H, Asil T, Celik Y, Tezel A, Dokmeci G, Tuncbilek N, et al. Cerebral sinus thrombosis in patients with inflammatory bowel disease: a case report. World J Gastroenterol 2005; 11:5404–5407.
12. Younes-Mhenni S, Derex L, Berruyer M, Nighoghossian M, Philippeau S, Salzmann M, Trouillas P. Large-artery stroke in a young patient with Crohn's disease. Role of vitamin B6 deficiency-induced hyperhomocysteinemia. J Neurol Sci 2004; 221:113–115.
13. Levy PJ, Tabares AH, Olin JW. Lower extremity arterial occlusions in young patients with Crohn's colitis and premature atherosclerosis: report of six cases. Am J Gastroenterol 1997; 92:494–497.
14. Novotny DA, Rubin RJ, Slezak FA, Porter JA. Arterial thromboembolic complications of inflammatory bowel disease. Report of three cases. Dis Colon Rectum 1992; 35:193–196.
15. Ashkan K, Nasim A, Sayers RD, Dennis MJ. Arterial thrombosis: a complication of loop ileostomy. Eur J Gastroenterol Hepatol 1998; 10:795–796.
16. Irving PM, Pasi KJ, Rampton DS. Thrombosis and inflammatory bowel disease. Clin Gastroenterol Hepatol 2005; 3:617–628.
17. Van Bodegraven AA. Haemostasis in inflammatory bowel diseases: clinical relevance. Scand J Gastroenterol Suppl 2003; 38:51–62.
18. Hayat M, Ariens RA, Moayyedi P, Grant PJ, O'Mahony S. Coagulation factor XIII and markers of thrombin generation and fibrinolysis in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2002; 14:249–256.
19. Chiarantini E, Valanzano R, Liotta AA, Cellai AP, Fedi S, Ilari I, et al. Hemostatic abnormalities in inflammatory bowel disease. Thromb Res 1996; 82:137–146.
20. Souto JC, Martinez E, Roca M, Mateo J, Pujol J, Gonzalez D, Fontcuberta J. Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease. Dig Dis Sci 1995; 40:1883–1889.
21. Oldenburg B, Van Tuyl BA, van der Griend R, Fijnheer R, van Berge Henegouwen GP. Risk factors for thromboembolic complications in inflammatory bowel disease: the role of hyperhomocysteinaemia. Dig Dis Sci 2005; 50:235–240.
22. Solem CA, Loftus EV, Tremaine WJ, Sandborn WJ. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol 2004; 99:97–101.
23. Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol 2005; 129:307–321.
24. Koutroubakis IE, Sfiridaki A, Tsiolakidou G, Coucoutsi C, Theodoropoulou A, Kouroumalis EA. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease. Eur J Gastroenterol Hepatol 2008; 20:912–916.
25. Saibeni S, Bottasso B, Spina L, Bajetta M, Danese S, Gasbarrini A, et al. Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases. Am J Gastroenterol 2004; 99:1966–1970.
26. Donmez A, Aksu K, Celik HA, Keser G, Cagirgan S, Omay SB, et al. Thrombin activatable fibrinolysis inhibitor in Behçhet's disease. Thrombosis Res 2005; 115:287–292.
27. Bouma MB, Koschinsky ML. Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Clin Biochem 2007; 40:431–442.

fibrinolysis; inflammatory bowel disease; plasminogen activator inhibitor-1; thrombin-activatable fibrinolysis inhibitor

© 2008 Lippincott Williams & Wilkins, Inc.